Adeno-Associated Virus Characterization with Agilent 6545XT AdvanceBio LC/Q-TOF and Protein Metrics Byos Software

Significance of the Topic

The characterization of adeno-associated viruses (AAVs) is critical for gene therapy development, ensuring product safety, efficacy, and regulatory compliance. Key quality attributes such as post-translational modifications (PTMs), host cell protein (HCP) impurities, and sequence variants (SVs) can impact vector performance and patient outcomes.

Objectives and Study Overview

This application note presents an integrated liquid chromatography–mass spectrometry (LC/MS) workflow using the Agilent 1290 Infinity II LC coupled to the 6545XT AdvanceBio LC/Q-TOF and Protein Metrics Byos software. The aim is to simultaneously assess AAV CQAs—intact capsid composition, PTMs, HCP profiling, and SV analysis—in a single, sample-limited experiment.

Methodology and Instrumentation

• Sample Preparation: Buffer exchange and denaturation, reduction, alkylation, and digestion using trypsin and rAsp-N.
• Chromatography: Peptide mapping and intact analysis on an AdvanceBio peptide mapping column (2.1×150 mm) at 60 °C with a water/acetonitrile gradient containing 0.1% formic acid.
• Mass Spectrometry: Agilent 6545XT Q-TOF with dual Agilent Jet Stream source, iterative MS/MS acquisition, and large-molecule SWARM autotune.
• Data Analysis: Byos software for reconstruction, HCP identification, SV validation, and PTM mapping.

Main Results and Discussion

• Intact Capsid Analysis: Reconstruction revealed shoulder peaks attributable to low-abundance PTMs not initially resolved.
• PTM Characterization: Mapping identified multiple phosphorylation and acetylation sites across VP1, VP2, and VP3 proteins.
• HCP Profiling: Iterative MS/MS detected contaminant proteins including trypsin, Asp-N, keratin, and a heat shock protein at low abundances.
• Sequence Variant Analysis: Six SVs were confirmed with EIC ratios; two Ser→Asn misincorporations exceeded 1% due to G/U codon mismatches.

Benefits and Practical Applications

This unified LC/MS approach reduces sample consumption and analysis time compared to separate assays. It enables comprehensive CQA monitoring in one workflow, accelerating AAV development and quality control processes.

Future Trends and Opportunities

Advances in high-resolution mass spectrometry and software automation will further improve sensitivity for ultra-low-abundance impurities. Integration with upstream analytics and real-time data processing may enable in-line quality monitoring during bioprocessing.

Conclusion

The described Agilent 1290/6545XT LC/Q-TOF workflow coupled with Protein Metrics Byos provides a robust, efficient, and sensitive platform for in-depth AAV characterization, addressing critical needs in gene therapy vector development.

Reference

1. Hale WA, Colangelo CM. Characterization of Viral Vector Particles Using the Agilent 6545XT AdvanceBio LC/Q-TOF. Agilent Technologies Application Note; 2020.
2. Liau B. LC/MS of Intact Adeno-Associated Virus Capsid Proteins for Rapid Confirmation of Product Identity. Agilent Technologies Application Note; 2020.
3. Huang Y, et al. J Pharm Biomed Anal. 2021;200:114069.
4. Valliere-Douglass J, et al. PDA J Pharm Sci Technol. 2019;73:622–634.
5. Zhang A, et al. mAbs. 2020;12(1):1791399.
6. Zhang Z, et al. Biochemistry. 2013;52:8165–8176.